Dr. Jennifer Litton is a board certified medical oncologist and associate professor of breast medical oncology at the University of Texas MD Anderson Cancer Center in Houston, where she is chief of the Section of Clinical Research and Drug Development for Breast Cancer. She also is a member of the Breast Immuno-Oncology Task Force of the National Cancer Institute.Listen to the podcast to hear Dr. Litton discuss:

how immunotherapy medicines work

why immunotherapy medicines haven’t seemed to work as well in breast cancer as they have in other cancers

the direction of immunotherapy research for breast cancer

Running time: 13:35

Dr. C. Kent Osborne is director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, where he is also a professor and the Dudley and

Tina Sharp Chair for Cancer Research. Since 1992, he has been a codirector of

the San Antonio Breast Cancer Symposium, the world's largest conference

focusing entirely on breast cancer. His own research focuses on improving the

effectiveness of hormonal therapy medicines and targeted therapies that treat

HER2-positive disease. At the 2018 American Association for Cancer Annual

Meeting, Dr. Osborne was honored with the 2018 AACR Distinguished Award for

Extraordinary Scientific Achievement and Leadership in Breast Cancer Research,

in part for his stewardship of the San Antonio Symposium.

Listen to the podcast to hear Dr. Osborne discuss:

how our understanding of breast cancer has

changed since the 1970s

the most promising areas of breast cancer

research going on right now

the feasibility of a cure for breast cancer

Running time: 12:06

Dr. Utthara Nayar is a research fellow in medicine at the Dana-Farber Cancer Institute, the Harvard Medical School, and the Broad Institute of MIT and Harvard. A cancer biologist, her broad research focuses on the interface of basic biology, targeted medicines, and drug resistance. At the 2018 American Association for Cancer Research Annual Meeting, she presented research looking at how acquired HER2 mutations can make some metastatic hormone-receptor-positive breast cancers resistant to hormonal therapy.

Listen to the podcast to hear Dr. Nayar explain:

the number of metastatic hormone-receptor-positive breast cancers that become resistant to hormonal therapy

what whole exome sequencing is and why she and her colleagues used it in this study

the possibility that genetic sequencing of cancers could be an ongoing part of treatment at some point in the future

Running time: 15:08

Desirée

Walker, who calls herself a two-time breast cancer "victor," talks about

her poster on the importance of involving patients in breast cancer research

projects.Running time: 5:23

Sheila McGlown, who was diagnosed with metastatic breast

cancer 5 years after her mother died of the disease, talks about her work with

the Shades of Brown Foundation to advocate for, educate, and support African

American women diagnosed with breast cancer.Running time: 3:02

Dr. Levi Garraway, senior vice president of oncology

development and medical affairs at Eli Lilly and Company, discusses some of the

research highlights at the 2018 AACR Annual Meeting, particularly those in breast

cancer.

 Running time: 3:06

Artist Kathryn Stella, vice president of The Bodice

Project, discusses how the sculptural exhibit promotes inner healing among women and men who

have been diagnosed with breast cancer.

Running time: 3:44

Dr. Utthara Nayar is a research fellow in medicine at the Dana-Farber Cancer Institute, the Harvard medical School, and the Broad Institute of MIT and Harvard. A cancer biologist, her broad research focuses on the interface of basic biology, targeted medicines, and drug resistance. At the 2018 American Association for Cancer Research Annual Meeting, she's presented research looking at how acquired HER2 mutations can make some metastatic hormone-receptor-positive breast cancers resistant to hormonal therapy.

Listen to the podcast to hear Dr. Nayar explain:

the number of metastatic hormone-receptor-positive breast cancers that become resistant to hormonal therapy

what whole-exome sequencing is and why she and her colleagues used it in this study

the possibility that genetic sequencing of cancers could be an ongoing part of treatment at some point in the future

Running time: 15:08

Dr. C. Kent Osborne is director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, where his is also a professor and the Dudley and

Tina Sharp Chair for Cancer Research. Since 1992, he has been a codirector of

the San Antonio Breast Cancer Symposium, the world's largest conference

focusing entirely on breast cancer. His own research focuses on improving the

effectiveness of hormonal therapy medicines and targeted therapies that treat

HER2-positive disease. At the 2018 American Association for Cancer Annual

Meeting, Dr. Osborne was honored with the 2018 AACR Distinguished Award for

Extraordinary Scientific Achievement and Leadership in Breast Cancer Research,

in part for his stewardship of the San Antonio Symposium.

Listen to the podcast to hear Dr. Osborne discuss:

how our understanding of breast cancer has

changed since the 1970s

the most promising areas of breast cancer

research going on right now

the feasibility of a cure for breast cancer

Running time: 12:06